尿路感染产超广谱β-内酰胺酶大肠埃希菌的检测及耐药性分析  

Detection and Antibiotic Resistance Analysis of Escherichia Coli Producing Broad-spectrum β-lactamases in Urinary Tract Infections

作　　者：邓海芬 Deng Haifen(Clinical Laboratory,The Affiliated Baiyun Hospital of Guizhou Medical University,Guiyang,Guizhou 550081)

机构地区：[1]贵州医科大学附属白云医院检验科,贵州贵阳550081

出　　处：《科技与健康》2024年第12期105-108,共4页Technology and Health

摘　　要：检测尿路感染产超广谱β-内酰胺酶大肠埃希菌(extended-spectrum β-lactamases,产ESBLs)并分析其耐药性.选取2021年6月-2023年6月于贵州医科大学附属白云医院接受尿路感染治疗的80例患者为研究对象,采集患者中段尿样后分别进行细菌鉴定、药敏试验和产ESBLs检测,统计病原菌分布情况、大肠埃希菌产超广谱β-内酰胺酶检测情况、对比产ESBLs与非产ESBLs对常用抗生素的耐药性,统计影响产ESBLs尿路感染的因素.结果显示,检出革兰阴性菌49株,其中大肠埃希菌占比最大,产ESBLs检出率为32.35%,且大部分产ESBLs对常见抗生素的耐药性均高于非产ESBLs.研究发现,产ESBLs是引起尿路感染的主要病原菌,需通过多种检测方式联合检测,其较高的耐药性给临床治疗带来了较大的负面影响,可根据患者实际身体状况为其选择其他药物进行治疗,需严格注意用法用量.Detect extended spectrumβ-lactamases(ESBLs)producing Escherichia coli in urinary tract infections and analyze their drug resistance.Eighty patients who received treatment for urinary tract infections at The Affiliated Baiyun Hospital of Guizhou Medical University from June 2021 to June 2023 were selected as the research subjects.Middle stage urine samples were collected from patients and bacterial identification,drug sensitivity testing,and ESBLs production testing were performed.The distribution of pathogens,detection of Escherichia coli producing broad-spectrumβ-lactamase,comparison of resistance of ESBLs production and non ESBLs production to commonly used antibiotics,and factors affecting ESBLs production in urinary tract infections were analyzed.The results showed that 49 strains of Gram negative bacteria were detected,with Escherichia coli accounting for the largest proportion.The detection rate of ESBLs producing bacteria was 32.35%,and most ESBLs producing bacteria showed higher resistance to common antibiotics than non ESBLs producing bacteria.Research has found that ESBLs production is the main pathogen causing urinary tract infections and requires multiple testing methods to be combined.Its high drug resistance has a significant negative impact on clinical treatment.Other drugs can be selected for treatment based on the patient’s actual physical condition,and strict attention should be paid to the dosage and dosage.

关 键 词：尿路感染 产超广谱Β-内酰胺酶 耐药性 

分 类 号：R978.1[医药卫生—药品]